Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Abstract

Under the section "Adjuvant chemotherapy for early-stage disease"Long-term follow-up of the ICON 1 trial confirms the benefit of adjuvant chemotherapy, particularly in those patients at higher risk of recurrence (stage 1B/C grade 2/3, any grade 3 or clear-cell histology) [34]. Therefore, adjuvant chemotherapy should be offered not only to suboptimally staged patients but also to those optimally staged at higher risk of recurrence [I, A].

Clinical application of the sentinel lymph node technique in early ovarian cancer: a pilot study

“…In this case, it determines the prognosis and adjuvant systemic treatment needed,7 as the incidence of positive lymph nodes in patients with early-stage ovarian cancer is between 10–20% 8. Theoretically, the omission of an adequate lymphadenectomy in an early clinical stage may lead to the exclusion of adjuvant chemotherapy due to the under-diagnosis of lymph node metastasis.…”

Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review

“…6,7 Nearly 80% of OC patients have an initial favorable response to platinum-based (or sometimes paclitaxel-based) treatment; however, relapse and resistance to chemotherapy are common, resulting in treatment challenges for recurrent disease. 8,9 Approximately 70% of patients with advanced epithelial OC experience disease progression within the first 3 years of follow-up.…”

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer

“…10,11 The guidelines produced by various oncological organizations at least now suggest that patients should be offered a choice, although some are more in favor of routine CA125 measurements than others. 12,13 It seemed that those who accepted our advice were older and had a higher relapse rate than those who opted for routine CA125 measurements. No association could be demonstrated between tumor stage, grade and histological subtype, and choice of CA125 monitoring in this audit.…”